<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21269">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829983</url>
  </required_header>
  <id_info>
    <org_study_id>NMRBA</org_study_id>
    <nct_id>NCT02829983</nct_id>
  </id_info>
  <brief_title>Clarithromycin as Adjuvant to Periodontal Debridement</brief_title>
  <official_title>Clarithromycin as Adjuvant to Periodontal Debridement in the Treatment of Generalized Aggressive Periodontitis: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Estadual Paulista Júlio de Mesquita Filho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Estadual Paulista Júlio de Mesquita Filho</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the periodontal clinical response and the possible adverse effects of the
      clarithromycin combined to periodontal mechanical therapy in the treatment of patients with
      generalized aggressive periodontitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the periodontal clinical response and the possible adverse effects of the
      clarithromycin combined to periodontal mechanical therapy in the treatment of patients with
      generalized aggressive periodontitis.Forty patients were select and randomly assigned into
      two groups: Group clarithromycin with 20 subjects that received one-stage full-mouth
      ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3
      days; group placebo with 20 subjects that received FMUD associated with placebo. Probing
      depth (PD), gain in clinical attachment level (CAL) and bleeding on probing (BOP) were
      evaluated at baseline, 3 and 6 months post- operatively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical attachment level</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Probing depth</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Aggressive Periodontitis</condition>
  <arm_group>
    <arm_group_label>clarithromycin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Use of 500mg of Clarithromycin twice a day for 3 days</description>
    <arm_group_label>clarithromycin group</arm_group_label>
    <other_name>macrolide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Use of placebo tablets twice a day for 3 days.</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>One-stage full-mouth ultrasonic debridement (FMUD)</intervention_name>
    <description>One session of Periodontal debridement using ultrasonic device.</description>
    <arm_group_label>clarithromycin group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of Generalized Aggressive Periodontitis

          -  presence of ≥20 teeth

          -  presence of ≥ 6 sites presenting probing depth (PD) ≥5mm with bleeding on probing
             (BOP) and ≥2 sites with PD ≥7mm (including incisors and first molars, in addition to
             two other non-contiguous teeth between them)

          -  good general health

          -  &lt;35 years of age

          -  agree to participate in the study and sign a written consent

        Exclusion Criteria:

          -  pregnant or lactating

          -  suffering from any other systemic disease (e.g. cardiovascular, diabetes, blood
             dyscrasias, immunodeficiency, etc) which could alter the course of periodontal
             disease

          -  received antimicrobials in the previous 6 months

          -  taking long-term anti-inflammatory drugs

          -  received a course of periodontal treatment within the last 12 months

          -  smoked
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauro P Santamaria, DDS, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UPECLIN HC FM Botucatu Unesp</affiliation>
  </overall_official>
  <results_reference>
    <citation>Casarin RC, Peloso Ribeiro ED, Sallum EA, Nociti FH Jr, Gonçalves RB, Casati MZ. The combination of amoxicillin and metronidazole improves clinical and microbiologic results of one-stage, full-mouth, ultrasonic debridement in aggressive periodontitis treatment. J Periodontol. 2012 Aug;83(8):988-98. doi: 10.1902/jop.2012.110513.</citation>
    <PMID>22288485</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 12, 2016</lastchanged_date>
  <firstreceived_date>July 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Estadual Paulista Júlio de Mesquita Filho</investigator_affiliation>
    <investigator_full_name>Mauro Pedrine Santamaria</investigator_full_name>
    <investigator_title>DDS,MS,PhD</investigator_title>
  </responsible_party>
  <keyword>clarithromycin</keyword>
  <keyword>periodontal debridement</keyword>
  <keyword>aggressive periodontitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Aggression</mesh_term>
    <mesh_term>Aggressive Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
